Stone JH, Wallace Z, Perugino CA, et al. Final Results of an Open Label Phase 2 Study of a Reversible B Cell Inhibitor, Xmab®5871, in IgG4-Related Disease. ACR 2017, abstract 4L.
Samenwerking reumazorg Ziekenhuis Gelderse Vallei en Sint Maartenskliniek
sep 2022 | Arthritis psoriatica, Artritis, Artrose, JIA, Jicht, RA, Sclerodermie, Sjögren, Spondyloartritis